VANCOUVER, April 7 /CNW/ - EnWave Corporation (TSX-V: ENW) ("EnWave" or
"the Company") today announced the successful completion of tests using its
recently developed powderREV technology in the dehydration of cultures and
probiotics from the Danish group Danisco. The tests were conducted as the
first phase of an Agreement signed with Danisco last year. The objective of
the agreement is to create a dehydration method delivering high-speed
continuous bulk powder processing capable of handling sensitive biological
materials, such as cultures.
powderREV is a new Radiant Energy Vacuum (REV) process designed to
convert a liquid stream of biological materials into bulk powder on a
continuous basis. Preliminary tests on cultures were conducted at EnWave's
Vancouver lab using the single-vial REV prototype. Post-dehydration
bioactivity levels from the REV dehydration methods show that REV-dried
cultures are capable of achieving equivalent, or possibly better bioactivity
for certain cultures than freeze-dried samples.
Based on the success of these early results, EnWave and Danisco will now
undertake the second phase of the Agreement to evaluate the commercial
viability of EnWave's powderREV dehydration technology on a wider scope. The
terms of the Agreement grant Danisco with exclusivity for a limited period of
time. EnWave and Danisco expect this second phase to be completed in the 2nd
quarter of 2010.
"We are excited by the opportunity to test our new powderREV technology
with a leading global player in the food culture industry," said Dr. Tim
Durance chairman and Co-CEO of EnWave. "We intend to build on the success of
the phase one tests and look forward to exploring future collaboration
opportunities with Danisco".
With 7,200 employees operating from more than 80 locations in the world,
Danisco reported annual revenues of 18.7 billion DKK (US$3.1 billion) in its
2007/2008 year end results. The Danish group is a global leading supplier of
cultures and probiotics for food, supplements and feed and holds a dominant
position in cultures under dried form. Easier to handle, dried cultures bring
greater flexibility to manufacturers in terms of storage volume and conditions
as well as shelf-life stability.
"Danisco has always been proactive in searching for innovative
technologies to improve the drying process of cultures," said Egon Bech
Hansen, Danisco's Cultures Division Vice President R&D. "The initial results
from the tests with EnWave's technology are encouraging. We are looking
forward to expanding the testing on a larger scale prototype to better
evaluate potential product and economic advantages".
If powderREV technology can demonstrate commercial feasibility on a
scale, schedule and terms acceptable to both parties, EnWave would plan to
enter a commercial sales and exclusive license agreement with Danisco.
With a rich and innovative portfolio, Danisco is a world leader in food
ingredients, enzymes and bio-based solutions. Using nature's own materials,
science and the knowledge of our 7,200 people, Danisco designs and delivers
bio-based ingredients that meet market demand for healthier and safer
products. Danisco's ingredients are used globally in a wide range of
industries - from bakery, dairy and beverages to animal feed, laundry
detergents and bioethanol - offering functional, economic and environmental
benefits. Headquartered in Denmark and operating from more than 80 locations,
Danisco's key focus is to become customers' first choice and a truly
market-driven global business. Find out more at www.danisco.com.
Using proprietary technologies developed in conjunction with the
University of British Columbia, EnWave is focused on the development of new
methods of dehydrating biological and food materials using Radiant Energy
Vacuum technology under its bioREVTM, freezeREV, nutraREVTM and powderREV
brands. REV technology combines microwave energy transfer with pressure
control to dehydrate and alter structures and drive chemical reactions,
thereby creating unique product characteristics for both food products and
medical applications that include dry vaccines and antibodies. More
information about EnWave is available at www.enwave.net.
Mr. John McNicol
President & Co-CEO
This press release may contain forward-looking information based on
management's expectations, estimates and projections. All statements that
address expectations or projections about the future, including statements
about the Company's strategy for growth, product development, market position,
expected expenditures and financial results are forward-looking statements.
The forward-looking statements in this press release include: "EnWave intends
to" and "EnWave expects". These statements are not a guarantee of future
performance and involve a number of risks, uncertainties and assumptions:
there is no guarantee that the Company's powderREV technology can or will
improve processes in the food culture industry; even if the Company's
powderREV technology can be used as described in this document, there is no
guarantee that such use will result in orders for the Company's powderREV
The TSX Venture Exchange has neither approved nor disapproved the
information contained herein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Mr. John McNicol, President and Co-CEO at (604)
601-8524, Email: firstname.lastname@example.org; Mr. Egon Bech Hansen, Vice President
Research and Development Cultures Division Danisco A/S, +45 24 82 15 70 (DK);
Jennifer Thompson, V.P. Corporate Development & Investor Relations at (604)
603-6549, Email: email@example.com